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Alzheimer’s disease (AD) is characterized by the presence of amyloid
β (Aβ) plaques, tau tangles, inflammation, and loss of cognitive function. Genetic variation in a cholesterol transport protein, apolipoprotein E (apoE), is the most common genetic risk factor for sporadic AD.
In vitro evidence suggests that apoE links to Aβ production through
nanoscale lipid compartments (lipid clusters), but its regulation in vivo
is unclear. Here, we use superresolution imaging in the mouse brain
to show that apoE utilizes astrocyte-derived cholesterol to specifically
traffic neuronal amyloid precursor protein (APP) in and out of lipid
clusters, where it interacts with β- and γ-secretases to generate Aβpeptide. We find that the targeted deletion of astrocyte cholesterol
synthesis robustly reduces amyloid and tau burden in a mouse model
of AD. Treatment with cholesterol-free apoE or knockdown of cholesterol synthesis in astrocytes decreases cholesterol levels in cultured
neurons and causes APP to traffic out of lipid clusters, where it interacts with α-secretase and gives rise to soluble APP-α (sAPP-α), a neuronal protective product of APP. Changes in cellular cholesterol have
no effect on α-, β-, and γ-secretase trafficking, suggesting that the
ratio of Aβ to sAPP-α is regulated by the trafficking of the substrate,
not the enzymes. We conclude that cholesterol is kept low in neurons,
which inhibits Aβ accumulation and enables the astrocyte regulation
of Aβ accumulation by cholesterol signaling.
Alzheimer’s

membrane contributes to APP processing (11, 14, 15) (SI Appendix,
Fig. S1A). Testing this hypothesis in vivo has been hampered by the
small size and transient nature of lipid clusters (often <100 nm),
which is below the resolution of light microscopy.
Superresolution imaging has emerged as a complimentary technique to DRMs, with the potential to interrogate cluster affinity
more directly in a native cellular environment (16). We recently
employed superresolution imaging to establish a membranemediated mechanism of general anesthesia (17). In that mechanism, cholesterol causes lipid clusters to sequester an enzyme away
from its substrate. Removal of cholesterol then releases and activates the enzyme by giving it access to its substrate (SI Appendix,
Fig. S1C) (7, 18). A similar mechanism has been proposed to
regulate the exposure of APP to its cutting enzymes (11, 15, 19–21).
Neurons are believed to be the major source of Aβ in normal
and AD brains (22, 23). In the adult brain, the ability of neurons
to produce cholesterol is impaired (24). Instead, astrocytes make
cholesterol and transport it to neurons with apolipoprotein E
Significance
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A

lzheimer’s disease (AD), the most prevalent neurodegenerative
disorder, is characterized by the progressive loss of cognitive
function and the accumulation of amyloid β (Aβ) peptide and
phosphorylated tau (1). Amyloid plaques are composed of aggregates
of Aβ peptide, a small hydrophobic protein excised from the transmembrane domain of amyloid precursor protein (APP) by proteases
known as beta- (β-) and gamma- (γ-) secretases (SI Appendix, Fig.
S1A). In high concentrations, Aβ peptide can aggregate to form Aβ
plaques (2–4). The nonamyloidogenic pathway involves a third enzyme, alpha- (α-) secretase, which generates a soluble APP fragment
(sAPP-α), helps set neuronal excitability in healthy individuals (5),
and does not contribute to the generation of amyloid plaques.
Therefore, by preventing Aβ production, α-secretase–mediated
APP cleavage reduces plaque formation. Strikingly, both pathways
are finely regulated by cholesterol (6) (SI Appendix, Fig. S1B).
In cellular membranes, cholesterol regulates the formation of
lipid clusters (also known as lipid rafts) and the affinity of proteins
to lipid clusters (7), including β-secretase and γ-secretase (8–10).
α-secretase does not reside in lipid clusters; rather, α-secretase is
thought to reside in a region made up of disordered polyunsaturated
lipids (11). The location of APP is less clear. In detergent-resistant
membrane (DRM) studies, it primarily associates with lipid from
the disordered region, although not exclusively (8, 10, 12–14).
Endocytosis is thought to bring APP in proximity to β-secretase
and γ-secretase, and this correlates with Aβ production. Cross-linking
of APP with β-secretase on the plasma membrane also increases
Aβ production, leading to a hypothesis that lipid clustering in the
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(apoE) (25–27). Interestingly, apoE, specifically the e4 subtype
(apoE4), is the strongest genetic risk factor associated with sporadic
AD (28, 29). This led to the theory that astrocytes may be controlling
Aβ accumulation through regulation of the lipid cluster function (11,
15, 19), but this has not yet been shown in the brain of an animal.
Here, we show that astrocyte-derived cholesterol controls Aβ accumulation in vivo and links apoE, Aβ, and plaque formation to a
single molecular pathway.
Results

Downloaded at SCHL MED LIB&77680003 on September 7, 2021

Characterization of Astrocyte-Derived Cholesterol on Neuronal Cluster
Formation. To establish a role for Aβ regulation by astrocytes in vivo,

we first labeled and imaged monosialotetrahexosylganglioside1
(GM1) lipids in wild-type (WT) mouse brain slices. GM1 lipids
reside in cholesterol-dependent lipid clusters and bind cholera toxin
B (CTxB) with high affinity (30, 31). These GM1 domains are
separate from phosphatidylinositol 4,5 bisphosphate domains, which
are polyunsaturated and cholesterol independent (18, 32, 33). We
labeled GM1 domains (i.e., lipid clusters) from cortical slices with
Alexa Fluor 647–conjugated, fluorescent CTxB and imaged with
confocal and superresolution direct stochastical optical reconstruction microscopy (dSTORM) (34–37). dSTORM is capable of visualizing nanoscale arrangements [i.e., sub–100-nm diameter lipid
domain structures (38)] in intact cellular membranes.
CTxB appeared to label most cell types in cortical brain slices
(SI Appendix, Fig. S2A, green shading). In neurons, labeled with a
neuron-specific antibody against neurofilament medium (NFM)
chain protein, CTxB can be seen outlining the plasma membrane
(outside of the cell), as opposed to NFM which labels throughout
the cells (SI Appendix, Fig. S2 A, Right).
Next, we investigated the role of cholesterol on the relative size
and number of neuronal GM1 domains in brain tissue (Fig. 1A)
using dSTORM (a ∼10-fold increase in resolution compared to
confocal). In WT mouse cortical tissue, GM1 domains averaged
∼141 nm in apparent diameter, slightly smaller than the apparent
size in primary neurons (∼150-nm diameter) (Fig. 1B). Cultured
neuroblastoma 2a (N2a) cells exhibited the smallest clusters by far,
on average only 100 nm in apparent diameter. All of the mammalian cells had domains larger than an intact fly brain, which had
an apparent diameter of ∼90 nm (17). CTxB is pentadentate and
can affect the absolute size; here, we used the numbers merely as a
relative comparison of size under identical conditions (SI Appendix).
In order to determine if astrocytes were a key cholesterol source
regulating GM1 lipid domains, we compared the size of GM1
domains in neurons cocultured with cholesterol-deficient astrocytes. We depleted astrocyte cholesterol by SREBP2 gene ablation
(SREBP2−/−). SREBP2 is an essential regulator of cholesterol
synthesis enzymes (39) and was specifically knocked out in astrocytes using an ALDH1L1 promoter-driven Cre recombinase (40).
We found that when cholesterol was depleted from astrocytes, the
cluster size of primary neurons was significantly reduced (130 nm).
The observed effect of astrocyte SREBP2 ablation on neurons suggests the decreased cholesterol transport to neurons—presumably
through apoE.
To confirm that astrocytes could regulate neuronal GM1 domain formation through apoE, we added purified apoE to cultured primary neurons and N2a cells. The apoE (human subtype
3) derived from Escherichia coli was devoid of cholesterol, as
prokaryotes do not make cholesterol. To provide a source of
cholesterol to the apoE, we added 10% fetal bovine serum (FBS),
a common source of mammalian lipids, including ∼310 μg/mL
cholesterol-containing lipoproteins. ApoE can both load and unload cholesterol from cells, including neurons (41–43) (see also SI
Appendix). To confirm apoE’s effect in transporting cholesterol,
we incubated apoE with N2a cells and analyzed the extracted
lipids with mass spectrometry. The main apoE component
extracted from the cells is cholesterol, including free cholesterol
and cholesterol ester (Fig. 1C). Importantly, apoE is not present in
2 of 12 | PNAS
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FBS (44). Cells were treated acutely (1 h) with 4 μg/mL apoE, a
physiologically relevant concentration seen in cerebral spinal
fluid (45).
Loading cells with cholesterol (apoE and +FBS) caused an
increase in the apparent cluster diameter from 100 to 130 nm in
N2a cells (Fig. 1D). When cholesterol was unloaded, (ApoE absent a cholesterol source), the apparent size and number of GM1
domains decreased (Fig. 1 D and E and SI Appendix, Fig. S2B).
Binning clusters by large >500 nm and small <150 nm showed a
clear shift toward smaller domains, with apoE in low cholesterol,
and a clear shift to large domains, with apoE in high cholesterol
(SI Appendix, Fig. S2 C and D). We also measured cholesterol
extraction by apoE in N2a cells using a quantitative absorbance
assay. ApoE decreased the total cholesterol by ∼5% (SI Appendix,
Fig. S2E). To confirm this result, we compared apoE treatment
to treatment with methyl β-cyclodextrin (MβCD), a nonnative
chemical binder that extracts cholesterol from the plasma membrane and disrupts cluster function (46). MβCD caused a similar
decrease, as seen for cells with cholesterol effluxed (SI Appendix,
Fig. S2 O and P).
We also investigated apoE’s effect in modulating membrane
cholesterol level and lipid cluster integrity using an enzymatic
cluster disruption assay. The disruption assay uses phospholipase
D (PLD) as a reporter of cluster disruption (18). After 1 h incubation with apoE (−Chol), PLD activity significantly increased,
confirming cluster disruption (SI Appendix, Fig. S2F). We confirmed that apoE decreased the N2a total cellular cholesterol in
the plasma membrane (Fig. 1F) using a live cell fluorescent cholesterol assay (see Materials and Methods). When incubated with
cholesterol, apoE loads cholesterol into the cells. These results
suggest a functional role of apoE in extracting/loading cellular
cholesterol and modulate lipid clusters in cellular membranes. The
live cell assay reduces pipetting errors and allows for a precise
comparison of a treatment versus its control (Fig. 1F).
Superresolution Imaging of Amyloid-Processing Proteins in Lipid
Clusters. Next, we sought to characterize a cellular function of

cholesterol loading (i.e., the ability of GM1 domains to move APP
toward or away from its hydrolyzing secretases). To establish the
movement of APP to each of its processing enzymes, α-, β-, and
γ-secretases, directly in cellular membranes, we imaged N2a cells
with dSTORM. APP was previously found in both cluster- and
noncluster-like fractions of DRMs (8, 10, 12–14). DRMs are
similar to GM1 lipid clusters. However, imaging APP is important,
since the amount of cluster-like association in DRMs could easily
be affected by the detergent concentration used for preparation.
We labeled GM1 domains with fluorescent CTxB and the amyloid
proteins (APP, α-, β-, and γ -secretases) with Cy3b-labeled, fluorescent antibodies and determined cluster localization by pair
correlation using density-based spatial clustering of applications
with noise of two-color dSTORM images (Fig. 2A).
Fig. 2B shows that APP, β-secretase, and γ-secretase are associated with GM1 clusters (i.e., they exhibit strong pair correlation with CTxB-labeled GM1 lipids at short distances [5 nm]),
consistent with experiments in DRMs.
In contrast, α-secretase is not associated with GM1 domains
(i.e., lacks pair correlation with CTxB) (Fig. 2B). The pair correlation
(a unitless number) ranged from 10 to 15 for APP, β-secretase, and
γ-secretase, while the pair correlation for α-secretase was <3, a value
typical for little or no pair correlation, a result also consistent with
previous experiments in DRMs (15).
Cellular Regulation of APP Exposure to α- and β-Secretase by apoE.

We then investigated the ability of apoE to mediate the delivery
of cholesterol to cell membranes and regulate Aβ production in
N2a cells. We applied 4 μg/mL human apoE isoform 3 (apoE3),
purified from E. coli with and without cholesterol, and measured
APP localization to lipid clusters with dSTORM. We found that
Wang et al.
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Fig. 1. Astrocyte cholesterol signals to membrane nanostructure in neurons. (A) dSTORM superresolution imaging on WT brain slices showing lipid
cluster nanostructure in cell membrane. (Scale Bar, 2 μm.) (B) Comparison of
apparent cluster length in N2a cells; primary neurons cultured with astrocytes with and without (SREBP−/−) cholesterol synthesis and brain slices. Data
are expressed as mean ± SEM and n = 1,748 to 6,779 clusters from >3 images.
(C) Mass spectrometry analysis showing that the majority of lipids extracted
by apoE (a cholesterol transport protein) from N2a cells are cholesterol.
Some cluster-associated lipids are also transported by apoE. Abbreviations
for lipids: FC, free cholesterol; CE, cholesterol ester; SM, sphingomyelin;
dhSM, dihydrosphingomyelin; and Pep, plasmalogen phosphatidylethanolamine. (D) Quantitation of cluster lengths in N2a cells indicates changes in
cluster structure after apoE treatment with and without a source of cholesterol (± chol). Data are expressed as mean ± SEM and n = 1,911 to 6,779
clusters from four to seven cells. (E) Quantitation of GM1 clusters in N2a cells
shows that apoE decreased the number of clusters under low-cholesterol
conditions, while apoE treatment with high, environmental cholesterol
doesn’t affect cluster number. Data are expressed as mean ± SEM and oneway ANOVA. (F) Exposure of N2a cells to apoE removes cholesterol from
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levels and cluster formation in neurons (Fig. 1), we hypothesized
that astrocytes could directly control Aβ production in neuronal
membranes. To test this hypothesis, we cultured primary cortical
cells from mouse embryos (E17). In a first culture, we isolated just
the neurons by sorting the cells with live cell fluorescence-activated
cell sorting (FACS) with Thy1.2, a cell surface marker of mature
neurons. In a second culture, we did not remove contaminating
astrocytes from neurons, resulting in a mixed culture. All cultures were treated with or without apoE, fixed, and labeled with
appropriate fluorophores; the neurons were then imaged with
dSTORM. We confirmed the presence of astrocytes in our mixed
culture by staining for glial fibrillary acidic protein (GFAP).
About 1% of the mixed cell population was labeled by the GFAP
antibody (SI Appendix, Fig. S3F).
We found that the incubation of purified cortical neurons
(Thy1.2+ with no astrocytes) with cholesterol-free human apoE
dramatically decreased APP association with GM1 domains
(>twofold) (Fig. 3B) in primary neurons. However, when we mixed

cellular membranes, as measured by a fluorescent-based live cell cholesterol
assay. Cholesterol loading by apoE increases cellular cholesterol level. Data
are expressed as mean ± SEM, n = 4 to 7, one-way ANOVA, *P < 0.05, ***P <
0.001, and ****P < 0.0001.
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when ApoE loaded cholesterol into cells (apoE +FBS), APP
association with GM1 domains was almost twofold higher than
when apoE effluxed cholesterol (apoE and −FBS) (Fig. 2 C–E
and SI Appendix, Fig. S2 G and H). In a control experiment, FBS
alone (+Chol with no apoE added) did not increase APP trafficking to lipid clusters (Fig. 2 C and D and SI Appendix, Fig.
S2 G and H), confirming that apoE is a specific and necessary
mediator of cholesterol transport to the neuron. This result also
confirms previous mass spectrometry results (44) that there is no
appreciable apoE in FBS—if apoE were already present, then
adding more would not have had such a dramatic effect. Moreover, apoE alone (under low-cholesterol condition [−FBS]) decreased APP clustering (Fig. 2 B and C and SI Appendix, Fig.
S2G), confirming that exogenously added apoE can unload
cholesterol in neuronal membranes. ApoE efflux was similar to
MβCD treatment (SI Appendix, Fig. S2 O–S) (11, 15).
Surprisingly, neither cholesterol loading nor the unloading of
N2a cells had a significant effect on α-, β-, or γ-secretase trafficking in or out of GM1 domains (Fig. 2E and SI Appendix, Fig.
S2 I–N). GM1 domains were analyzed pairwise for association
with either α-, β-, or γ-secretase in an identical manner to APP.
In contrast to APP, cholesterol unloading with apoE treatment
was insufficient to move β- or γ-secretase out of GM1 domains.
Likewise, more cholesterol failed to increase the association of
any of the secretases. α-secretase, located in the disordered region, remained in the disordered region (Fig. 2 B and E and SI
Appendix, Fig. S2 I and J), while β- and γ-secretases, which were
already in the lipid clusters, did not increase their association with
GM1 lipids in cholesterol-loaded cells (Fig. 2 B and E and SI Appendix, Fig. S2 K–N). This suggests that a mobile substrate (APP)
moves between relatively static enzymes (secretases) in the plasma
membrane. An enzyme-linked immunosorbent assay (ELISA)
confirmed a shift from Aβ40 to sAPP-α production under lowcholesterol condition and increased Aβ40 generation in highmembrane cholesterol (Fig. 2F). Fig. 2 G and H summarizes the
substrate moving between the different secretases based on
cluster-associated, apoE-dependent trafficking and the expected
cleavage products based on localization. With low cholesterol,
apoE moves APP to α-secretase, generating more sAPP-α (Fig.
2 H, Top). During high cholesterol, apoE moves APP to β- and
γ-secretase, which produce Aβ peptide (Fig. 2 H, Bottom).

Protein

+

Pair Correlation

Labeling

5
0

30
20
10
0

0

-s
ec

100 200 300 400 500

0

Radius (nm)

100 200 300 400 500

80
60
40
20
0
on

tr

n.s.

n.s.
n.s. n.s.

***

120

sAPP Percentage (%)

n.s.

C

ApoE (-Chol)
ApoE (+Chol)

200

****

***

100

Radius (nm)

*

300

+Chol

-Chol

120

ol

-s

-s

ec

ec

0

40

F

n.s.

100

**

ol

10

Control (+Chol)
+ApoE

tr

15

Radius

50

on

10

20

D

+A
po
E

20

Control (-Chol)
+ApoE

A 40 Percentage (%)

APP & GM1
Pair Correlation

30

p=0.0550

100
80
60
40
20

H

DISORDERED REGION
Low Cholesterol

+A
po
E

ol
tr
on

γ-sec

C

ol

β-sec

tr

α-sec

on

APP

G

+A
po
E

0

0
C

Relative Changes in
Pair Correlation with GM1 (%)

E

25

APP & GM1
Pair Correlation

C

40

AP
P

Pair Correlation with GM1

dSTORM
Super-resolution
Imaging

C

ApoE

B

Radius

Cluster Analysis

+A
po
E

GM1

Pair Correlation

A

Low Cholesterol Condition

Cholesterol

GM1 Cluster

ApoE

High Cholesterol

GM1 cluster

APP

α-secretase

H Cholesterol Condition
High

ApoE

α secretase
α-secretase

Amyloid
Amy
yloid
Precursor
Precu
ursor
Protein

β
secretase
β-secretase

γ-secretase
secretase

Downloaded at SCHL MED LIB&77680003 on September 7, 2021

APP

β-secretase

γ-secretase

Fig. 2. APP is regulated by cholesterol, not its hydrolytic enzymes. (A) Workflow for dSTORM superresolution. Cultured cells (blue) are depicted in a dish.
Cells were exposed to apoE with and without cholesterol supplementation and fixed. GM1 lipids and amyloid proteins were fluorescently labeled (CTxB and
antibody, respectively) and imaged with superresolution (dSTORM). The proximity of the two labels (shown as red and green circles) was then determined by
cluster analysis. Idealized pair correlations are shown for objects that strongly colocalize (Top) and weakly colocalize (Bottom) at a given radius. Pair correlations are unitless with 1 being little to no correlation and >5 a value typically significant in our experimental conditions. (B) α-secretase sits in the disordered region (low correlation with GM1 lipid clusters), while APP, β-, and γ-secretases are GM1 associated in N2a cells. (C and D) Pair correlation analysis
showing that APP moving in (C) and out (D) of the GM1 clusters under high- and low-cholesterol conditions, respectively. (E) Under low-cholesterol conditions
(−Chol), APP colocalization with GM1 clusters decreases markedly after apoE treatment. Under high-cholesterol conditions (+Chol), apoE-mediated APP
colocalization with GM1 clusters increases (i.e., apoE induces APP to cluster with GM1 lipids). α-, β-, and γ-secretase localization do not respond to apoEmediated GM1 clustering. (F) ELISA in N2a cells showing a shift from Aβ to sAPP-α production after apoE treatment under low-cholesterol condition and
increased Aβ production under high-cholesterol condition. Data are expressed as mean ± SEM, n = 3 to 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001,
n.s. (not significant), and two-sided Student’s t test. (G and H) Because of cluster disruption mediated by apoE, APP is dissociated from GM1 clusters under lowcholesterol conditions, exposing it to α-secretase to be cleaved into nonamyloidogenic sAPP-α. With high, environmental cholesterol, apoE-induced cluster
stabilization mediates more APP to be translocated into lipid clusters and cleaved by β- and γ-secretase, producing amyloidogenic Aβ peptides.
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The In Vivo Role of Astrocyte Cholesterol on Aβ and Plaque Formation
in Mouse Brain. Cholesterol is high in AD brains (1, 6). Our model

predicts that the attenuation of cholesterol in astrocytes should
reduce the concentration of Aβ peptide formed in vivo. To test
this hypothesis and to investigate the effect of astrocyte cholesterol on Aβ plaque formation in the intact brain, we crossed
3xTg-AD mice, a well-established mouse model with AD pathology (49), with our SREBP2flox/flox GFAP–Cre mice (47) to
generate an AD mouse model lacking astrocyte cholesterol. In
vivo Aβ exists in several forms, with Aβ1 to Aβ40 being the most
abundant and Aβ1 to Aβ42 the most closely associated with AD
pathology. The 3xTg-AD mouse expresses transgenes for mutant
human APP and mutant presenilin 1 enzyme, resulting in a significant increase in human Aβ40 and Aβ42 production.
Using ELISAs, we measured human APP transgene-derived
Aβ40 and Aβ42 in both the radioimmunoprecipitation assay
buffer (RIPA) –soluble and –insoluble fractions in the hippocampus of aged control and transgenic AD mice. Hippocampus
tissue from WT control mice was assessed to determine the
Wang et al.
Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol

nonspecific background of the Aβ signal in each ELISA. Knockout
of SREBP2 in astrocytes of 3xTg-AD mice (AD × SB2−/−) reduced soluble Aβ40 and Aβ42 levels in the hippocampus of
60-wk-old mice by twofold, to levels only slightly higher than WT
controls (Fig. 4A), suggesting a near complete loss of amyloidogenic processing of APP. More impressively, insoluble Aβ40 and
Aβ42 were almost entirely eliminated from the AD × SB2−/−
hippocampus (Fig. 4A). This was verified by immunofluorescence
staining demonstrating an absence of amyloid plaques in AD ×
SB2−/− mice (Fig. 4B). Of note, total APP transgene expression
was not impacted by the loss of astrocyte SREBP2 (SI Appendix,
Fig. S6A). Additionally, total GFAP and ApoE protein levels were
not significantly changed by SREBP2 ablation (SI Appendix, Fig.
S6B). To further confirm that the reduced Aβ plaque burden in
our model was due to reduced amyloidogenic processing, we
performed mixed primary cultures of astrocytes and neurons from
these 3xTg crosses. In agreement with our in vivo observation, we
found that astrocyte SREBP2 deletion modestly increased sAPP-α
production and robustly reduced sAPP-β generation without
changing total APP abundance (Fig. 5 A–C). The 3xTg-AD model
also expresses a transgene for human tau protein, another key
component of Alzheimer’s pathology. Tau is hyperphosphorylated
in AD, and this is thought to be downstream of Aβ accumulation
(50). It has also been proposed that cholesterol directly regulates
tau phosphorylation (51, 52). In agreement with both of these hypotheses, phosphorylation of tau at the key T181 residue, but not
total tau, is eliminated in vivo in the AD × SB2−/− hippocampus and
reduced in mixed cultures in vitro (Figs. 4 C and D and 5C and SI
Appendix, Fig. S6A). We also observed reduced brain tissue volume
in AD × SB2−/− animals, similar to that of astrocyte-specific SB2−/−
mouse brains characterized in our previous studies (47).
The Role of Astrocytic apoE in Regulating Membrane Cholesterol.

Although apoE is the major cholesterol transport protein in the
brain, there are other proteins that may also contribute significantly
to cholesterol transportation in the central nervous system. To test
the effect of astrocytic apoE in transporting cholesterol, we treated
neurons with astrocyte-conditioned media (ACM) from APOE
knockout mice and compared the cholesterol loading effect with
neurons treated with WT ACM (Fig. 6A). Specifically, we cultured
neurons from SREBP2 GFAP–Cre mice to eliminate the transport
of cholesterol from contaminating astrocytes in the culture. Neurons were treated with neurobasal media conditioned with astrocytes from WT or APOE−/− animals. In Western blot, we verified
that APOE−/− ACM contains no apoE, while WT ACM does (SI
Appendix, Fig. S7). Compared with control neurons without ACM
treatment, WT ACM significantly increased APP’s association with
GM1 clusters, while APOE−/− ACM did not show any effect
(Fig. 6B). This result again confirms that astrocytic apoE is required
for cholesterol transportation from astrocytes to neurons. Other
cholesterol transport proteins in the brain may allow some delivery
of cholesterol, but apoE is the major protein for transporting cholesterol into neurons under these culture conditions.
Isoform Specificity of ApoE. As mentioned, the apoE4 isoform is a
strong genetic risk factor for late onset AD. If this effect is in part
through cholesterol loading, we would expect to see a difference in
APP’s submembrane localization. To study the difference between
apoE3 and apoE4 in vivo, we analyzed the brain tissue from APOE
knock in (KI) mice, in which the human APOE variants (e3 and e4)
replace the endogenous murine Apoe locus (termed E3F and E4F
mice individually). We assessed these mice both alone and after
crossing them with mice with amyloid deposition in the brain by
crossing the different APOE-KI mice with APP/PS1 transgenic
mice. We found that an increased association of APP with GM1
lipids in E4F compared to E3F (Fig. 6C). Interestingly, overexpression of mutant APP and mutant PS1 (APP/PS1) with
resulting amyloid deposition has an even more dramatic effect
PNAS | 5 of 12
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astrocytes with neurons, the same apoE had the exact opposite
effect. GM1 domains sequestered APP, evident by a 2.5-fold increase in APP association with GM1 lipids (Fig. 3C). This suggests
that apoE delivers cholesterol from the astrocytes to the neurons
and increases GM1 domain affinity for APP. Similar imaging of the
secretases showed that they remained immobile with α-secretase
in the disordered region and β-secretase in GM1 domains (SI
Appendix, Fig. S3). Thus, astrocyte-derived cholesterol is a potent
signal that controls APP association with α- or β-secretase in the
neuron, based on GM1 domain affinity.
To further establish astrocyte-derived cholesterol as the regulator
of APP association with secretases, we specifically knocked down
cholesterol synthesis in astrocytes by knocking out the SREBP2
gene using a tamoxifen-inducible Cre recombinase system (Fig. 3A).
SREBP2 is the master transcriptional regulator of the majority of
enzymes involved in cholesterol synthesis. Mice with SREBP2
knocked out of astrocytes have reduced the production of cholesterol in the astrocytes (47) (SI Appendix, Fig. S4A). We cultured
cortical neurons and astrocytes from E17 pups and treated them
with 100 nM 4-hydroxytamoxifen for 2 d to induce knockout of
astrocyte SREBP2. Around 3 d after 4-hydroxytamoxifen removal,
the cells were fixed and labeled, and APP localization was imaged
with dSTORM, identical to the FACS-sorted neurons above (see
diagrams in Fig. 3).
Fig. 3D shows a highly significant decrease in APP pair correlation with GM1 domains in mixed cultures containing SREBP2
(−/−) astrocytes, similar to purified Thy1.2+ neuronal cultures
(Fig. 3B). Control cells from Thy1.2+ neurons and SREBP2 (−/−)
neuron/astrocyte cultures were very similar; the amplitude of pair
correlation was ∼10 for both cultures. 4-hydroxytamoxifen treatment did not significantly alter APP GM1 pair correlation in the
absence of Cre recombinase (SI Appendix, Fig. S4B).
We next examined if astrocytes contribute cholesterol to promote APP presence in neuronal lipid clusters in vivo. Astrocyte
cholesterol synthesis was disrupted in mice by crossing SREBP2
floxed mice to GFAP-Cre mice, resulting in a homozygous deletion of SREBP2 from astrocytes (47). At 4 wk of age, brains were
collected, and APP-GM1 pair correlation was determined in
neurons by dSTORM imaging. SREBP2 deletion in astrocytes
resulted in a robust and significant reduction of APP-GM1 pair
correlation compared to littermate controls (Fig. 3E). This suggests that astrocyte cholesterol synthesis plays an essential role in
maintaining cholesterol content in neuronal lipid clusters. These
data further confirmed that astrocyte-derived cholesterol regulates
APP translocation and association with secretases in the plasma
membrane of neurons. Neurons appear incapable of increasing
cholesterol synthesis to compensate for astrocyte deficiency in any
appreciable way (48).

A

ALDH1L1

4-HT

Cre ERT2

ALDH1L1

Cre ERT2

4-hydroxytamoxifen

X

ALDH1L1

Cholesterol
Synthesis

Cre ERT2
LoxP

LoxP

LoxP

SREBP2

SREBP2

SREBP2

LoxP

LoxP

LoxP

Astrocyte-Specific
Cholesterol Depletion
E17
4 week old

Wild Type Mice E17

FACS
Sorting
(Thy1.2+
Neuron)

Primary
Cortical
Cell Culture

Brain
Slicing

4-HT

dSTORM
Super-resolution
Imaging

**

150
100
50

*
ol
SR
EB
P/-

0

tr

M
i
ul xed
tu
re
+A
po
E

APP & GM1
Pair Correlation (%)

50

**

0

0
+A
po
E

T
N hy1
eu .2
ro +
n

0

n.s.

100

on

50

200

150

C

*

C

100

400

APP & GM1
Pair Correlation (%)

150

200

200

*

on

600

APP & GM1
Pair Correlation (%)

APP & GM1
Pair Correlation (%)

200

E

D

C

C

tr
ol
SR
EB
P/SR
E
+ B
ap PoE /-

B

Downloaded at SCHL MED LIB&77680003 on September 7, 2021

Fig. 3. Astrocyte cholesterol regulates APP processing in neurons. (A) Strategy for conditional knockout of SREBP2 in astrocytes using Cre-Lox recombination
system. SREBP2 flox mice were crossed to ALDH1L1-specific Cre transgenic mice, which express Cre recombinase specifically in astrocytes when presented
4-hydroxytamoxifen (4-HT). Cre promotes SREBP2 knockout and blocks cholesterol synthesis in astrocytes. (B–D) Cortical cells were isolated from
embryonic day 17 mice and cultured for dSTORM imaging. (B) ApoE translocates APP from lipid clusters into disordered regions in a pure, neuronal population sorted with cell surface neuronal marker Thy1.2. (C) ApoE increases APP’s cluster localization in primary neurons cultured in mixed population with
glia cells, including astrocytes. (D) Astrocyte-specific cholesterol depletion completely disrupts APP cluster localization in neurons in cultured cells. (E) Astrocyte cholesterol depletion disrupts APP cluster localization in vivo, as demonstrated in SREBP2fl/fl GFAP–Cre+/− mouse brain slices. Data are expressed as
mean ± SEM, n = 3 to 10, *P < 0.05, **P < 0.01, one-way ANOVA (D), or two-sided Student’s t test (B, C, and E).

than APOE genotype. Brain tissue from APP/PS1 mice has significantly increased APP-GM1 association (Fig. 6C). We also
measured the tissue cholesterol level of the brains and observed
a similar trend, as we found in APP-GM1 pair correlation.
Though not statistically significant, the E4F brains have a slightly
higher cholesterol level than E3F brains (Fig. 6D). Similarly, the
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APP/PS1/E4F brains have a slightly higher cholesterol level than
APP/PS1/E3F brains (Fig. 6D). APP/PS1 overexpression robustly
increases brain tissue cholesterol level (Fig. 6D).
Lastly, we tested the effect of purified apoE3 or apoE4 proteins to selectively transport cholesterol. We incubated N2a cells
with purified apoE proteins with or without cholesterol exposure
Wang et al.
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Fig. 4. Loss of cholesterol synthesis in astrocytes blocks Aβ plaque formation and Tau phosphorylation in vivo. 3xTg-AD mice (AD) were crossed to SREBP2fl/fl
GFAP–Cre+/− mice (AD × SB2−/−) and aged to 60 wk. (A) Hippocampus were isolated and soluble (RIPA extracted) and insoluble (guanidine extracted) Aβ40 and
Aβ42 species were measured by ELISA. (B) 60-wk-old brain slices stained for human Aβ (red) and DAPI (blue) in AD × SB2flox mice (Left) and AD × SB2−/− mice
(Right). (C) pTau levels were measured in 60-wk-old hippocampus lysate by ELISA. (D) 60-wk-old brain slices were immune stained for pTau (green) and Aβ
(red), and the subiculum region of the hippocampus was imaged. Data are expressed as mean ± SEM, n = 4 to 7, one-way ANOVA with Tukey’s post hoc
analysis, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

(Fig. 6E). Under low-cholesterol condition, both apoE3 and
apoE4 trafficked APP out of GM1 clusters into disordered regions, with no significant difference between the two isoforms
(Fig. 6F). Similarly, when exposed to high cholesterol, apoE3
and apoE4 increase APP’s cluster association with no significant
difference between isoforms (Fig. 6G). We also measured cellular cholesterol level after cholesterol extraction by apoE3 and
apoE4. Total cholesterol level decreased after apoE incubation.
We didn’t observe any difference between the two isoforms
(Fig. 6H). The results indicate that the difference in the in vivo
regulation is not a functional difference in the efficiency of an
isoform to transport cholesterol.
Discussion
Together, our data support astrocyte cholesterol as a key regulator of neuronal Aβ accumulation. The data from cultured
neurons and astrocytes show that astrocyte-secreted apoE loads
Wang et al.
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cholesterol into neurons. Increased cholesterol in neurons drives
APP to associate with β- and γ-secretases in lipid clusters. The
association of APP with lipid clusters appears to regulate the
amount of Aβ accumulation, and Aβ levels dictate insoluble
plaques (Fig. 7).
While it has been known for some time that astrocytes play an
important role in brain cholesterol production and express the
AD-related protein apoE, the role of astrocytes in AD pathogenesis remains poorly understood (53–55). Astrocytes undergo
robust morphological changes in neurodegenerative models, and
recent research demonstrates that astrocytes undergo broad
transcriptional changes early in the AD process (56). However,
whether astrocytes are simply reacting to the AD neurodegenerative cascade or playing a role in promoting disease remains
unclear. Here, we demonstrate a direct role for astrocytes in
promoting the AD phenotype through the production and distribution of cholesterol to neurons. Combined, our data establish
PNAS | 7 of 12
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Fig. 5. Astrocyte cholesterol regulates APP and Tau processing, not protein expression. Primary embryonic cultures of mixed neurons and astrocytes were
grown by crossing 3xTg SREBP2fl/fl mice with 3xTg SREBP2fl/fl GFAP–Cre mice. Each culture was grown independently from a single embryo, and Cre genotype
was confirmed by PCR. (A) Human sAPP-α levels (from transgenic APP) were measured in conditioned media from mixed cultures. (B) Protein in conditioned
media was precipitated, and sAPP-β, an APP fragment produced by β-secretase cleavage, was measured by Western blot. (C) Mixed cultures were lysed, and
protein content was examined by Western blot. Data are expressed as mean ± SEM and n = 4 per genotype. *P < 0.05 and ***P < 0.001.

a molecular pathway that connects astrocyte cholesterol synthesis with apoE lipid trafficking and amyloidogenic processing
of APP (Fig. 7). The pathway establishes cholesterol as a critical
lipid that controls the signaling state of a neuron. Cholesterol
appears to be down-regulated in neurons as part of a mechanism
to allow astrocytes to control APP presentation to proteolytic
enzymes in the neuron. By keeping cholesterol low, the astrocyte
can move the neuron through a concentration gradient that
profoundly affects APP processing and eventual plaque formation. In essence, cholesterol is set up to be used as a signaling
lipid. Rather than targeting a receptor, it targets GM1 domains
and sets the threshold for APP processing by altering GM1 domain function. This concept is likely important to other biological systems (57), given the profound effect of cholesterol on
human health.
The rise and fall of Aβ peptide with cholesterol is striking
(Fig. 4 A and B), and the data presented here support the proposed molecular mechanism in which amyloidogenic processing
of APP is promoted by cholesterol increasing APP interactions
with β- and γ-secretases through substrate presentation (SI Appendix, Fig. S1). This finding is in agreement with prior research,
implicating increased brain cholesterol content as a factor which
8 of 12 | PNAS
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promotes AD-associated amyloid pathology. Administration of
statins to guinea pigs significantly reduces Aβ levels in the cerebrospinal fluid (58), and statins reduced β secretase processing in
induced pluripotent stem cell (iPSC) –derived neurons (59). APP/
PS1 AD mice overexpressing a truncated active form of SREBP2
display an accelerated Aβ burden with aging (60). The conclusion
is further supported by the existence of a cholesterol binding site
in the APP protein (61). Our findings contribute to literature,
demonstrating that amyloidogenic processing of APP in cultured
cells occurs primarily in cholesterol-rich membrane domains (15,
62) and is consistent with cholesterol unloading decreasing Aβ
formation in cell culture (63) and on the plasma membrane (64).
Several lines of evidence suggest that cholesterol and its trafficking by lipoprotein particles also influences hyperphosphorylation
of tau in neurons. van der Kant et al. found that, by disrupting
cholesterol production using statins or enhancing cholesterol
clearance, both pTau and total tau levels were reduced in cultured
iPSC neurons (51). Interestingly, statins had no effect on neuronal
pTau levels in the presence of proteasome inhibitors, suggesting
that high levels of cholesterol in neurons may slow the intracellular
clearance of tau protein. Moreover, we recently demonstrated that
deletion of astrocyte apoE in a mouse model of tauopathy mitigates
Wang et al.
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Fig. 6. Astrocytic apoE is required for cholesterol transportation from astrocytes to neurons. (A) Cartoon diagram showing the experimental setup for
neuron culture with ACM. Neurons from SREBP2 GFAP–Cre mice were used to eliminate transport of cholesterol from contaminating astrocytes in the culture.
Neurons were cultured with ACM from either WT or APOE−/− astrocytes. (B) dSTORM superresolution imaging shows that astrocytic apoE is required for
regulating APP’s GM1 clustering in neurons. Neurons cultured with ACM-containing apoE increased APP’s clustering with GM1 lipids, while ACM from
APOE−/− animals fail to increase APP’s cluster association. (C) APP in APOE4 brains (E4F) are more clustered with GM1 lipids, compared with E3F. Aβ overexpression (APP/PS1) also robustly increases APP’s raft association. APP/PS1/E4F has slightly higher APP-GM1 pair correlation than APP/PS1/E3F. (D) Aβ
overexpression (APP/PS1) increases brain cholesterol level robustly. In both control and APP/PS1 animals, E4F has a slightly higher cholesterol level in brain
tissue compared with E3F. Data are expressed as mean ± SEM, n = 3 to 10, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and one-way ANOVA. (E) N2a
cells were treated with purified apoE3 or apoE4 proteins to compare their abilities to load and unload cholesterol (± Chol) from the plasma membrane. (F)
Under low-cholesterol condition, apoE extracts cholesterol from the cells, decreasing APP’s GM1 clustering. There is no significant difference between apoE3
and apoE4. (G) Under high-cholesterol condition, apoE loads cholesterol into the cells, increasing APP’s GM1 clustering. There is no significant difference
between apoE3 and apoE4. (H) Exposure of N2a cells to apoE removes cholesterol from cellular membranes, as measured by a fluorescent-based live cell
cholesterol assay. There is no significant difference between apoE3 and apoE4.
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Fig. 7. Astrocyte cholesterol-dependent regulation of amyloid processing in neurons through apoE. A model for amyloid production in the Alzheimer’s
brain. Cholesterol is synthesized in astrocytes and shuttled to neurons in apoE lipoprotein particles. Adding recombinant, cholesterol-containing apoE enriches
neuronal membrane cholesterol levels, while delipidated apoE reduces membrane cholesterol. Cholesterol loading of the neuronal membranes regulates Aβ
production by increasing APP interactions with β- and γ-secretase. In low-cholesterol membranes, APP interacts with α-secretase, generating sAPPα. When neuronal
membranes are loaded with cholesterol, APP increasingly interacts with β- and γ-secretases generating Aβ peptides, resulting in brain plaque formation over time.

pTau pathology, neurodegeneration, and synapse loss, though total
tau levels remained unchanged (65). This could indicate that distinct mechanisms exist for both exogenous and endogenous sources
of cholesterol in promoting pTau accumulation in neurons. In a
large study of Alzheimer’s pathology, APOE variants were shown to
have strong effects on tau tangle burden, with APOE4/E4 carriers
most adversely affected (66). Notably, a homozygous carrier of the
APOE Christchurch mutation was reported to be resistant to cognitive decline and pTau accumulation, even in the presence of a
presenilin 1 mutation and robust amyloid plaque deposition (67).
Thus, the reduced levels of pTau we observe when astrocyte
SREBP2 is ablated are likely driven by both reduced cholesterol
levels as well as the alleviation of amyloid burden, though the exact
mechanisms by which astrocyte cholesterol influences neuronal tau
phosphorylation require future investigations.
The trend toward increased levels of cholesterol in apoE4 KI
mice and the increased APP/GM1 clustering are consistent with
the increased cholesterol in familial AD patients, which leads to
the clustering of APP with lipid rafts (14) and the increased Aβ
production seen in neurons expressing apoE4 isoforms (68). We
saw no difference on the ability of purified apoE3 and apoE4 to
load or unload cholesterol into cultured cells (Fig. 6 F–H); we
10 of 12 | PNAS
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conclude that cellular regulation of apoE, or protein abundance,
is likely responsible apoE’s isoform-specific effects in vivo.
Cholesterol loading into glial cells is known to cluster inflammatory proteins and cause inflammation (69); hence, cholesterol in
APP regulation suggests a correlative link between inflammation in
AD and Aβ production. A previous study found gene expression–
controlled Aβ production (70). We saw dramatic changes in Aβ
production without any appreciable change to APP expression
levels (Fig. 5). Nonetheless, the two mechanisms are not mutually exclusive, and increased APP expression would be synergistic
with increased cutting in response to high cholesterol.
At the molecular level, cholesterol loading regulates two functions: 1) the localization of APP to GM1 domains and 2) the total
number of GM1 domains (Fig. 1 D and E). Palmitoylation drives
the cluster association of the majority of integral cluster proteins
(7), but β- and γ-secretases are also palmitoylated and remain
localized to GM1 lipids, suggesting a difference in relative affinity
or additional factors that facilitate its release from GM1 domains
[e.g., hydrophobic mismatch (71)].
Many channels are palmitoylated (72) and may respond to
apoE and GM1 lipid domain function similar to APP. Investigating the effect of astrocyte cholesterol on channels will be important for studying AD, since many of the palmitoylated channels
Wang et al.
Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol

Materials and Methods

Downloaded at SCHL MED LIB&77680003 on September 7, 2021

Cell Cultures. The primary neurons, embryonic day 17 brain cortices, were
harvested from embryos and cultured with neurobasal medium supplemented with 20% B27, 1% Glutamax, and 1% penicillin/streptomycin, while
tails from each individual embryo were collected for the determination of Cre
genotype. Astrocytes, N2a, and human embryonic kidney 293T cells were
grown in standard Dulbecco’s Modified Eagle Medium with 10% FBS.

Extended Methods for a complete description of all the antibodies and their
validation used for imaging.
Brain slices. Mouse brain was fixed in 4% paraformaldehyde and 20% sucrose/
PBS solution at 4 °C for 3 d and embedded in Tissue-Tek optimal cutting
temperature (OCT) compound (Sakura) and sliced sagittal (50 μm). Primary
and secondary antibodies were incubated for 3 d each with washing in
between and postfixation. Brain slices were mounted onto the 35-mm glass
bottom chamber (ibidi, No. 81158) with 2% agarose to form a permeable
agarose pad and prevent sample movement during imaging.
Amyloid and pTau ELISAs.
Cell cultures. Supernatants from cells or brain tissue were analyzed for the
presence of Aβ40 and sAPP-α with a commercial human Aβ40 ELISA kit
(Invitrogen, #KHB3481) following the manufacturer’s instructions or antirabbit APP antibody abcam, #ab15272. Human Aβ1 to Aβ40 (R&D Systems,
#DAB140B) and Aβ1 to Aβ42 (R&D Systems, #DAB142) were quantified in
mouse hippocampus tissue using commercially available ELISA kits per
manufacturer’s instructions. Whole hippocampus tissue was homogenized
from 60-wk-old female mice in RIPA buffer (Bioworld, #42020024–2) with
protease inhibitors.
Western Blots. The 40-wk-old mouse hippocampus tissue was homogenized
in RIPA buffer with protease inhibitors and run on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. Resolved protein was transferred to polyvinylidene difluoride membrane and blocked with a 5% BSA solution in PBS
with Tween 20. Primary antibodies against target proteins were applied
overnight at 4 °C and imaged with a fluorescent secondary antibody.
Lipidomics. Lipidomics profiling was performed using ultra-performance
liquid chromatography–tandem mass spectrometry by core services available from Columbia University.
Statistics. All statistical calculations were performed in GraphPad Prism
version 6.0. For the Student’s t test, significance was calculated using a twotailed, unpaired parametric test with significance defined as *P < 0.05, **P <
0.01, ***P < 0.001, and ****P < 0.0001. For the multiple comparison test,
significance was calculated using an ordinary one-way ANOVA with Dunnett’s
multiple comparisons test.
Data Availability. dSTORM and biochemical assay data have been deposited in
Mendeley (https://doi.org/10.17632/4s373hyhj6.1) (78). All other study data
are included in the article and/or supporting information.

dSTORM.
Fixed cells. Cells were incubated with 4 μg/mL purified apoE protein for 1 h in
media with or without 10% FBS supplementation and then fixed with 3%
paraformaldehyde and 0.1% glutaraldehyde for 15 min. Cells were permeabilized with 0.2% Triton X-100 for 15 min and then blocked with 10%
bovine serum albumin (BSA)/0.05% Triton in phosphate-buffered saline (PBS)
for 90 min at room temperature. Cells were labeled with primary antibody for
60 min and secondary antibody for 30 min at room temperature with blocking
then fixed again. We note that the anti-APP antibody (ab15272) used for
dSTORM was different from the anti-APP antibody (ab32136) used for Western blots. Both antibodies were previously validated; see SI Appendix,
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have profound effects on neuronal excitability and learning and
memory (72). In separate studies, we saw that cholesterol loading
with apoE caused the potassium channel TREK-1 to traffic to
lipid clusters similar to APP (73, 74)—an effect that was reversed
by mechanical force (75).
Our data suggest cultured cells lacking apoE supplementation
likely underestimate physiological GM1 domain size, especially
those derived from the brain where cholesterol is high (76). Not
surprisingly, clusters appeared to be absent in cultured cells (77). Not
until cholesterol, supplied by astrocytes or cholesterol-containing
apoE, was added were nanoscale clusters present (∼100 nm). We
conclude from our data that the conditions with cholesterol are
the more physiologically relevant conditions for cultured cells.
All astrocyte-targeting Cre lines also delete to some degree in
neural progenitor cells. While our model also suffers from this
shortcoming, we have previously demonstrated that overall cholesterol synthesis by neurons increases to compensate for the loss
of astrocyte cholesterol (47). Thus, the dramatic decrease in Aβ
and pTau that we observe in our AD × SB2(−/−) mice cannot
readily be explained by the minority of knocked out neurons. In
addition, microglia, which are also able to produce apoE (47) and
are not impacted by the Cre, are unable to compensate for a lack
of astrocyte cholesterol synthesis. Our data emphasize that the
small changes in Aβ production we see in our cell culture models
may have a meaningful impact in vivo, such that the cumulative
impact of altering cholesterol delivery to neurons can be observed.
We conclude that the availability of astrocyte cholesterol
regulates Aβ production by substrate presentation. This contributes to the understanding of AD and provides a potential
explanation for the role of cholesterol-associated genes as risk
factors for AD.
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